← Browse by Condition
Medical Condition

neuroendocrine tumor of the lung

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for neuroendocrine tumor of the lung sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 2
1
Top Sponsors
AC Camargo Cancer Center 1 trial
NCT06472388 Phase 2
Recruiting

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Enrollment
100 pts
Location
Brazil
Sponsor
AC Camargo Cancer Center
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology